You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
上海醫藥(02607.HK)年度歸母淨利50.93億元 同比增長13.28%
格隆匯 03-30 08:52

格隆匯3月30日丨上海醫藥(02607.HK)發佈2021年度業績公吿,報吿期內,公司實現營業收入2158.24億元(幣種為人民幣,下同),同比增長12.46%。其中醫藥工業實現收入250.98億元,同比增長5.71%,毛利率57.80%(其中60個重點品種銷售收入147.24億元,同比上升9.31%,平均毛利率71.38%);醫藥商業實現收入1907.26億元,同比增長13.42%。

報吿期內,公司實現歸屬於上市公司股東的淨利潤50.93億元,同比增長13.28%;歸屬於上市公司股東的淨利潤加研發費用合計為70.81億元,同比增長15.08%;歸屬於上市公司股東的扣除非經常性損益的淨利潤為40.01億元,同比增長4.70%,歸屬於上市公司股東的扣除非經常性損益的淨利潤加研發費用合計為59.88億元,同比增長9.32%。公司經營性現金流淨流入50.61億元,繼續保持高質量發展。報吿期內,公司研發投入達到25.03億元,同比增長26.94%,其中研發費用19.87億元,同比增長19.96%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account